Recent blog posts
Moderna Unveils Phase 1/2 Results for mRNA-1083
Latest Hotspot
3 min read
Moderna Unveils Phase 1/2 Results for mRNA-1083
16 October 2023
Moderna, Inc. reported encouraging preliminary outcomes from the mRNA-1083 Phase 1/2 study, a combination vaccine currently under investigation for its effect against both influenza and COVID-19.
Read →
Vedanta Biosciences Reports Initiation of Phase 2 l Study for VE202 in Ulcerative Colitis
Latest Hotspot
3 min read
Vedanta Biosciences Reports Initiation of Phase 2 l Study for VE202 in Ulcerative Colitis
16 October 2023
Vedanta Biosciences recently reported the initiation of treatment for the initial participant in the COLLECTiVE202 Phase 2 investigation of VE202.
Read →
BridgeBio and Resilience declares a collaboration aiming to progress BBP-631, BBP-812
Latest Hotspot
3 min read
BridgeBio and Resilience declares a collaboration aiming to progress BBP-631, BBP-812
16 October 2023
BridgeBio Pharma and National Resilience Inc., which focus on genetic diseases, cancer pharmaceuticals, and tech-driven biomanufacturing respectively, announced a partnership to develop and produce BBP-812 and BBP-631, gene therapies for Canavan disease and congenital adrenal hyperplasia.
Read →
Disc Medicine Launches Phase 1 Trial of DISC-3405 with Healthy Participants
Latest Hotspot
3 min read
Disc Medicine Launches Phase 1 Trial of DISC-3405 with Healthy Participants
16 October 2023
Disc Medicine has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.
Read →
Kineta Reports Encouraging Findings for KVA12123 Monotherapy from Phase 1/2 Clinical Study
Latest Hotspot
3 min read
Kineta Reports Encouraging Findings for KVA12123 Monotherapy from Phase 1/2 Clinical Study
16 October 2023
Kineta, Inc., a clinical-stage biotech firm specializing in unique cancer immunotherapies, has shared updates on their ongoing Phase 1/2 clinical trial of KVA12123 for advanced solid tumor patients.
Read →
First participant receives Cu-67 SAR-Bombesin treatment in theranostic prostate cancer study
Latest Hotspot
3 min read
First participant receives Cu-67 SAR-Bombesin treatment in theranostic prostate cancer study
16 October 2023
Clarity Pharmaceuticals proudly announces the initial patient dosing in their 64Cu/67Cu SAR-Bombesin Phase I/II theranostic trial for patients with metastatic castrate resistant prostate cancer.
Read →
REGENXBIO Reveals Clinical Information from Phase I/II Study of RGX-202
Latest Hotspot
3 min read
REGENXBIO Reveals Clinical Information from Phase I/II Study of RGX-202
16 October 2023
REGENXBIO Inc. disclosed further provisional safety information and preliminary effectiveness results from the phase I/II AFFINITY DUCHENNE™ study of RGX-202 aimed at treating Duchenne Muscular Dystrophy.
Read →
FDA approves Transcenta Phase III Study of Osemitamab for Gastric/Gastroesophageal Cancer
Latest Hotspot
3 min read
FDA approves Transcenta Phase III Study of Osemitamab for Gastric/Gastroesophageal Cancer
16 October 2023
Transcenta Holding Limited states that it has received the green light from FDA to continue with TranStar 301,This trial is conducted for Osemitamab (TST001) used together with Nivolumab and chemotherapy.
Read →
Syndax publicizes AUGMENT-101 Study reached its main objective involving Revumenib in KMT2Ar Acute Leukemia cases
Latest Hotspot
3 min read
Syndax publicizes AUGMENT-101 Study reached its main objective involving Revumenib in KMT2Ar Acute Leukemia cases
13 October 2023
Syndax Pharmaceuticals has reported encouraging preliminary figures following a protocol-defined collective examination of the essential AUGMENT-101 study on revumenib, a front-runner in the class of menin inhibitors.
Read →
SOLA Biosciences presented validation information for SOL-257, Targeting at misfolded TDP-43 in ALS
Latest Hotspot
3 min read
SOLA Biosciences presented validation information for SOL-257, Targeting at misfolded TDP-43 in ALS
13 October 2023
SOLA Biosciences is set to share its promising preliminary proof-of-concept data for SOL-257, a specific gene therapy aimed at misfolded TDP-43 in ALS.
Read →
Vertex shares results of Phase 1/2 trial of VX-880 for Type 1 Diabetes
Latest Hotspot
3 min read
Vertex shares results of Phase 1/2 trial of VX-880 for Type 1 Diabetes
13 October 2023
Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.
Read →
Preliminary Findings from NT219 Phase 1/2 Trial in Head & Neck Cancer Announced by Purple Biotech
Latest Hotspot
4 min read
Preliminary Findings from NT219 Phase 1/2 Trial in Head & Neck Cancer Announced by Purple Biotech
13 October 2023
Purple Biotech Ltd. shares clinical insights from its dose amplification segment of the Phase 1/2 trial of NT219.
Read →